Search

Your search keyword '"Songwit Payapwattanawong"' showing total 3 results
Start Over Author "Songwit Payapwattanawong"
3 results on '"Songwit Payapwattanawong"'

1. Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study

Author

Chanchai Charonpongsuntorn, Suebpong Tanasanvimon, Krittiya Korphaisarn, Songwit Payapwattanawong, Teerada Siripoon, Nussara Pakvisal, Jitlada Juengsamarn, Ekkamol Phaibulvatanapong, Jarin Chindaprasirt, Naiyarat Prasongsook, Kittipong Udomdamrongkul, Nuttapong Ngamphaiboon, and Ekaphop Sirachainan

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

PURPOSEAtezolizumab plus bevacizumab treatment is a first-line therapy for unresectable hepatocellular carcinoma (HCC) worldwide. The efficacy, safety, and patient-reported outcomes (PROs) of HCC in Thailand have not yet been reported. This study aimed to evaluate the efficacy, safety, and PROs of atezolizumab plus bevacizumab.MATERIALS AND METHODSFrom September 2020 to August 2021, 30 patients with unresectable HCC who met the inclusion criteria of atezolizumab plus bevacizumab as first-line treatment were enrolled. Analysis was assessed for progression-free survival, overall survival, adverse events (AEs), and quality of life (QoL).RESULTSThe median progression-free survival and overall survival periods were 6.7 and 10.2 months, respectively. The disease control rate was 63.3%. The frequent AEs were proteinuria, hypertension, and hepatitis. Serious AEs included gastrointestinal bleeding, but none of the patients died from serious AEs. The discontinuation rate was 23.3%, and the median number of treatment cycles was 10.5 cycles. In total, 23.3% of the patients continued treatment after 1 year of therapy. The global health status/QoL and physical function scores showed less deterioration at baseline than at 3 and 6 months (median scores = 76.7, 71.6, and 64.1 in QoL and 84.7, 79.6, and 79.0 in physical function, respectively). The HCC18 symptom score index data showed a slow progression of symptom scores from baseline to 3 and 6 months (12.7, 19.6, and 22.3, respectively).CONCLUSIONThis study demonstrates that atezolizumab plus bevacizumab is effective and has a safety profile comparable with that of previous studies as first-line therapy for unresectable HCC in a real-world setting and in Thai populations. Data on PROs also demonstrate benefits in terms of patients' QoL and symptoms.

Published
2022
Full Text
View/download PDF

2. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide

Author

Sunatee Sa-nguansai, Songwit Payapwattanawong, Wipada Nipondhkit, Kunlatida Maneenil, Jedzada Maneechavakajorn, Sudsawat Laohavinij, and Piyawan Tienchaiananda

Subjects
Adult, Olanzapine, Vomiting, Nausea, Placebo-controlled study, Breast Neoplasms, Placebo, Dexamethasone, Ondansetron, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Retching, 030212 general & internal medicine, Cyclophosphamide, Aged, Advanced and Specialized Nursing, business.industry, Palonosetron, Middle Aged, Treatment Outcome, Anesthesiology and Pain Medicine, Doxorubicin, 030220 oncology & carcinogenesis, Anesthesia, Antiemetics, Female, medicine.symptom, business, medicine.drug, Chemotherapy-induced nausea and vomiting
Abstract

Background: Since most of Thai cancer patients receiving high emetogenic chemotherapy do not have access to neurokinin-1 (NK-1) receptor antagonists or palonosetron as recommended by international guidelines for chemotherapy-induced nausea and vomiting (CINV) prevention. We decided to evaluate the efficacy of olanzapine with the real-life practice antiemetic drugs ondansetron and dexamethasone, in prevention of CINV resulting from doxorubicin plus cyclophosphamide regimen in early-stage breast cancer patients. Methods: In this randomized, double-blind, placebo-controlled trial, we compared olanzapine with a placebo in combination with ondansetron and dexamethasone in early-stage breast cancer patients receiving doxorubicin 60 mg/m 2 plus cyclophosphamide 600 mg/m 2 . The intervention group received olanzapine 10 mg orally while the control group received a matching placebo daily on day 1 through day 4. All patients received ondansetron 8 mg and dexamethasone 20 mg intravenously 30 minutes before chemotherapy administration and then dexamethasone 10 mg daily orally from day 1 through day 4. The primary endpoint was no nausea rate in the early period. The secondary endpoints were no nausea rate in the delayed and overall periods and a complete response (no vomiting and no use of rescue drug). Outcomes were determined by patients’ self-reported daily records of episodes of vomiting or retching, use of rescue therapy and daily levels of nausea based on a visual-analogue scale from the first cycle of chemotherapy. Results: A total of 39 female patients were randomized in a 1:1 ratio to receive olanzapine (20 patients) or a matching placebo (19 patients). A significantly greater proportion of patients reported no nausea in the olanzapine group than in the placebo group in both the early period (0–24 hours after chemotherapy) and the overall period (0–120 hours after chemotherapy). Patients who reported no nausea in the early period accounted for 50% and 10.5% in the olanzapine group and in the placebo group respectively (P=0.008). In the overall period, 30.0% and 0% of patients reported no nausea in the olanzapine and placebo groups respectively (P=0.009). In the early period, there was a significantly different complete response rate between two treatment groups; 75.0% in the olanzapine group and 36.8% in the placebo group (P=0.016). Overall treatment-related adverse events were not significantly different between the two study groups except that somnolence was significantly more common in the olanzapine group than in the placebo group. Conclusions: Olanzapine 10 mg combined with ondansetron and dexamethasone was more effective than a placebo in preventing CINV resulting from doxorubicin plus cyclophosphamide in early-stage breast cancer patients, especially in the first 24 hours after chemotherapy administration. The short duration of olanzapine was safe and well tolerated.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results